Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/22259
Full metadata record
DC FieldValueLanguage
dc.contributor.authorŞimşek, Şaban-
dc.contributor.authorDemirok, Ahmet-
dc.contributor.authorÇınar, Adnan-
dc.contributor.authorYaşar, Tekin-
dc.date.accessioned2021-10-07T07:22:47Z-
dc.date.available2021-10-07T07:22:47Z-
dc.date.issued1998-
dc.identifier.citationŞimşek, S. vd. (1998). "The effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd : YAG laser posterior capsulotomy". European Journal of Ophthalmology, 8(3), 167-172.en_US
dc.identifier.issn1120-6721-
dc.identifier.urihttps://doi.org/10.1177/112067219800800309-
dc.identifier.urihttps://journals.sagepub.com/doi/pdf/10.1177/112067219800800309-
dc.identifier.urihttp://hdl.handle.net/11452/22259-
dc.description.abstractPurpose. The efficacy and adverse effects of 0.25% apraclonidine on intraocular pressure (IOP) after Nd: YAG laser posterior capsulotomy were investigated, and the results were compared with placebo, 0.50% timolol maleate and 1% apraclonidine. Methods. Eighty eyes were randomly assigned to four groups of 20 eyes. In a double-masked design, the groups were treated with placebo (group I), 0.50% timolol maleate (group 2), 1% apraclonidine (group 3), 0.25% apraclonidine (group 4) one hour before and five minutes after Nd:YAG laser posterior capsulotomy. IOP was measured by applanation tonometry I hour before (baseline IOP) and 1, 3, 24 hours after capsulotomy. Results. The average baseline IOP increased respectively 3.90 +/- 5.35, 5.95 +/- 5.32, 1.15 +/- 3.20 mmHg in the first group 1, 3 and 24 hours post-treatment. There were significant differences between baseline IOP and 1 and 3 hours but not at 24 hours (p=0.004, p=0.001, p=0.13). IOP increased 0.40 +/- 4.08, 0.75 +/- 5.33, 0.80 +/- 6.03 mmHg in the second group at the same times. The differences between the average baseline IOP and the 1, 3 and 24 h measurement were not significant (p=0.83, p=0.65, p=0.93). In the third group, IOP decreased 3.70 +/- 2.40, 3.30 +/- 2.47, 2.65 +/- 1.56 mmHg at the measurement times, with significant differences between the average baseline IOP and the 1, 3 and 24 hour measurements (p=0.001, p=0.0001, p=0.01). In the fourth group IOP increased 0.35 +/- 3.32 mmHg at 1 hour, but decreased 1.25 +/- 3.41, 0.90 +/- 2. 07 mmHg at 3 and 24 hours. The differences were not significant (p = 0.94, p = 0.16, p = 0.08). When the 0.25% and 1% apraclonidine groups were compared, there were significant differences between the average IOP at 1 hour in both groups but not at 3 and 24 hours (p=0.01, p = 0.17, p = 0.21). Similarly, there were no significant differences between the average IOP at the same times when the 0.25% apraclonidine group was compared with the timolol group (p = 0.30, p = 0.08, p = 0.16). Some systemic and local side effects were seen in the timolol and 1% apraclonidine groups, but none with 0.25% apraclonidine. Conclusions. It was concluded that 0.25% apraclonidine is effective in preventing the early elevation of IOP after Nd:YAG laser posterior capsulotomy and may offer an alternative to 0.50% timolol maleate and 1% apraclonidine.en_US
dc.language.isoentr_TR
dc.publisherSage Publicationsen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOphthalmologyen_US
dc.subjectNd : YAG laseren_US
dc.subjectPosterior capsulotomyen_US
dc.subjectApraclonidineen_US
dc.subjectTimolol maleateen_US
dc.subject1-percent apraclonidineen_US
dc.subjectDose-responseen_US
dc.subjectNeodymiumen_US
dc.subjectTimololen_US
dc.subjectRiseen_US
dc.subjectEyesen_US
dc.titleThe effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd : YAG laser posterior capsulotomyen_US
dc.typeArticleen_US
dc.identifier.wos000077895200009tr_TR
dc.identifier.scopus2-s2.0-0031715452tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Göz Hastalıkları Anabilim Dalı.tr_TR
dc.identifier.startpage167tr_TR
dc.identifier.endpage172tr_TR
dc.identifier.volume8tr_TR
dc.identifier.issue3tr_TR
dc.relation.journalEuropean Journal of Ophthalmologyen_US
dc.contributor.buuauthorErtürk, Haluk-
dc.contributor.buuauthorKaradenizli, Caner-
dc.relation.collaborationYurt içitr_TR
dc.identifier.pubmed9793771tr_TR
dc.subject.wosOphthalmologyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubmeden_US
dc.contributor.scopusid7003716972tr_TR
dc.contributor.scopusid6503909861tr_TR
dc.subject.scopusCapsule Opacification; Phakic Intraocular Lenses; Capsulotomyen_US
dc.subject.emtreeApraclonidineen_US
dc.subject.emtreeTimolol maleateen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAnxietyen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBronchospasmen_US
dc.subject.emtreeCapsulotomyen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeControlled clinical trialen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDouble blind procedureen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeEarly diagnosisen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman cellen_US
dc.subject.emtreeHuman tissueen_US
dc.subject.emtreeIntraocular pressure abnormalityen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNeodymium laseren_US
dc.subject.emtreePhacoemulsificationen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreePunctate keratitisen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.